



- Stock: In Stock
- Model: 184271
0% Customers recommend this product
-
5 Awesome0%
-
4 Great0%
-
3 Average0%
-
2 Bad0%
-
1 Poor0%
Reviews Over Nalbufin-Pharmex solution for infection. 10mg/ml 1 ml No. 10
- (0)
Total Reviews (0)
click here write review to add review for this product.
Report this review.
Description
Nalbufin-Pharmex - opioid analgetic of group of agonists antagonists of opiate receptors. Indications – a pain syndrome of strong and average intensity; as an additional tool when carrying out anesthesia; for decrease in pain in before - and the postoperative period; anesthesia during childbirth.
Structure
- active ingredient: nalbuphine hydrochloride; 10 mg contain
- 1 ml of solution a hydrochloride of a nalbufin;
- other components: sodium chloride, sodium citrate, citric acid monohydrate, water for injections.
Contraindication
Hypersensitivity to a hydrochloride of a nalbufin or any of medicine components.
Children's age up to 18 years.
should not be applied in respiratory depression or the significant oppression of the central nervous system, the increased intracranial pressure, a head injury, acute alcohol poisoning, alcoholic psychosis, an obvious abnormal liver function and kidneys.
combined use of medicament with pure agonists of a morfinomimetika is not recommended to.
is not recommended to use medicament without performing the corresponding diagnostics at a surgical belly syndrome as nalbufin can mask its manifestations.
Medicine should not be applied to women during feeding by a breast (except for use cases during childbirth).
bySide reactions
At the patients who are treated nalbufiny most often observe drowsiness.
from the immune system: anaphylactic reactions.
from nervous system: dizziness, headaches, muscular rigidity, increase in intracranial pressure.
Mental disturbances: accustoming to drug, psikhomimetichesky reactions, neurotic reactions, drowsiness, a depression, confusion of consciousness, a dysphoria, disturbance of the speech, change of mood, concern, nervousness (restlessness), hallucinations, euphoria.
Possibility of physical and mental dependence and also tolerance during long-term treatment same, as well as for other derivatives of morphine.
from a gepatobiliarny system: disturbance of functional indicators of a liver, spasm of biliary tract.
from kidneys and urinary tract. antidiuretic effect, a spasm of urinary tract
from a reproductive system and mammary glands: lowering of a libido or potency.
from a digestive tract: nausea, vomiting, dryness in a mouth, spasms in a stomach, a constipation.
from a cardiovascular system: increase or decrease in the ABP, bradycardia, tachycardia, orthostatic hypotension, heartbeat.
from organs of sight: illegibility or disorder of vision, miosis.
from skin and hypodermic cellulose: urticaria, itching.
General disturbances and reactions in the place of drug: a hypothermia, there can be local pain, hypostasis, reddening, burning and caumesthesia, inflows, the increased perspiration.
Route of administration Medicine to appointby
for intravenous and intramuscular administration.
Dosage has to correspond to intensity of pain, a physical condition of the patient and consider interaction with other at the same time applied medicines. Usually at a pain syndrome it is necessary to enter intravenously or intramusculary from 0.15 to 0.3 mg on 1 kg of body weight of the patient; to enter a single dose of medicament if necessary each 3–6 hours.
Maximum single dose – 0.3 mg/kg of body weight, the maximum daily dose – 2.4 mg/kg of body weight.
In a myocardial infarction often happens enough 20 mg of medicament entered slowly into a vein however increase in a dose up to 30 mg can be required. In the absence of accurate positive dynamics of a pain syndrome – 20 mg repeatedly in 30 minutes.
For premedication – 100–200 mkg/kg of body weight. When carrying out an intravenous anesthesia for introduction to an anesthesia – 0.3-1 mg/kg within 10–15 minutes, for maintenance of an anesthesia – to 250-500 mkg/kg are each 30 minutes.
byWith care to appoint medicament sick advanced age, in the general exhaustion, insufficient function of breath.
Feature of use
At the patients having medicament addiction, medicine can cause a bad attack of abstinency.
Use during pregnancy or feeding by a breast
due to the lack of researches cannot appoint medicament during pregnancy or feeding a breast.
Childrennot to apply
. Ability to influence speed of response at control of motor transport or other mechanisms
during treatment should refrain from control of motor transport and work with other mechanisms.
OverdoseAt overdose the following symptoms are possible
: respiratory depression; arterial hypotension; circulatory unefficiency; deepening of a comma; spasms; a rhabdomyolysis that progresses to a renal failure. to apply
At treatment of overdose:
by- at an early stage to patients in consciousness activated coal inside;
- maintenance therapy (the oxygen, intravenous administration of replaceable liquid, means increasing arterial blood pressure);
- intravenous administration of Naloxonum (specific antidote).
Interaction with other medicines and other types of interactions
Under fixed observation and in the reduced doses should use medicament against the background of effect of anesthetics, somnolent drugs, anxiolytics, antidepressants and neuroleptics for prevention of excessive oppression of the central nervous system (CNS) and oppression of activity of a respiratory center. Alcohol also strengthens the oppressing action of a nalbufin on central nervous system. The medicament should not be taken together with other narcotic analgetics because of danger of weakening of analgeziruyushchy action and a possibility of provoking of a withdrawal at patients with dependence to opioids.
Combination to derivatives of a fenotiazin and medicaments of penicillin can strengthen nausea and vomiting.
Combined use is contraindicated to. Alfentanil, codeine, dekstroproksifen, dihydrocodeine, fentanyl, methadone, morphine, oxycodone, pethidine, sufentanil, tramadol – is observed reduction of analgesic effect as a result of blocking of receptors with risk of appearance of a withdrawal.
Combined use is not recommended to. Alcohol – increase in sedation of morfoanalgetik. Deterioration in attention can be dangerous at control of vehicles or work with other mechanisms. It is necessary to avoid consumption of alcoholic beverages and use of the medicines containing ethanol.
Storage conditionsto Store
in original packing at a temperature not over 25 ºС. To store out of children's reach.
Specifications
Characteristics | |
Active ingredients | Nalbufin |
Amount of active ingredient | 10 mg/ml |
Applicant | Pharmex Group |
Code of automatic telephone exchange | N02AF02 Nalbufin |
Interaction with food | It doesn't matter |
Light sensitivity | Not sensitive |
Market status | Generic-generic |
Origin | Chemical |
Prescription status | According to the prescription |
Primary packing | ampoule |
Producer | LTD COMPANY PHARMEX GROUP |
Quantity in packing | 10 ampoules on 1 ml |
Release form | solution for injections |
Route of administration | Intravenous |
Sign | Domestic |
Storage temperature | from 5 °C to 25 °C |
Trade name | Nalbufin |